SEC Comment Letter 0000000000-23-012931 to TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
Date: Nov. 28, 2023 · CIK: 0001733413 · Accession: 0000000000-23-012931
AI Filing Summary & Sentiment
File numbers found in text: 333-275692
Letter
United States securities and exchange commission logo November 28, 2023 Harlan Weisman, M.D. Chief Executive Officer TFF Pharmaceuticals, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107 Re:TFF Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 21, 2023 File No. 333-275692 Dear Harlan Weisman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue, Esq.
Show Raw Text
United States securities and exchange commission logo
November 28, 2023
Harlan Weisman, M.D.
Chief Executive Officer
TFF Pharmaceuticals, Inc.
1751 River Run, Suite 400
Fort Worth, Texas 76107
Re:TFF Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 21, 2023
File No. 333-275692
Dear Harlan Weisman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel K. Donahue, Esq.